Biotechnology Assets, S.A.

Equities

BST

ES0184980003

Biotechnology & Medical Research

Delayed BME Other stock markets 09:05:20 03/07/2024 pm IST			5-day change	1st Jan Change
0.333 ^EUR	0.00%		+0.91%	-15.91%

05/04	Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	CI

ADL Bionatur S A : Modificación en la composición del Consejo de Administración de ADL Bionatur Solutions (05/08/2020)

August 05, 2020 at 10:32 pm IST

OTRA INFORMACIÓN RELEVANTE

ADL BIONATUR SOLUTIONS, S.A.

5 de agosto de 2020

En virtud de lo previsto en el artículo 17 del Reglamento (UE) nº 596/2014 sobre abuso de mercado y en el artículo 227 del texto refundido de la Ley del Mercado de Valores, aprobado por el Real Decreto Legislativo 4/2015, de 23 de octubre, y disposiciones concordantes, así como en la Circular 6/2018 del Mercado Alternativo Bursátil (MAB), se pone a disposición del mercado la siguiente información:

MODIFICACIÓN EN LA COMPOSICIÓN DEL CONSEJO DE ADMINISTRACIÓN DE ADL BIONATURSOLUTIONS,

S.A. Y DE SU COMISIÓN DE NOMBRAMIENTOS Y RETRIBUCIONES

Con efectos desde el 5 de agosto de 2020, D. Harrison A. Bubrosky ha presentado su renuncia como miembro del Consejo de Administración de ADL Bionatur Solutions, S.A. (la "Sociedad"), que implica igualmente su cese como miembro de la Comisión de Nombramientos y Retribuciones de la Sociedad.

En Jerez de la Frontera, a 5 de agosto de 2020

ADL Bionatur Solutions, S.A.

D. Jaime Feced Rubio

Consejero Delegado

Attachments

Original document
Permalink

Disclaimer

ADL Bionatur Solutions SA published this content on 05 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2020 17:01:08 UTC

Latest news about Biotechnology Assets, S.A.

Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	05/04	CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	11/23/11	CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	13/22/13	CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	13/22/13	CI
ADL Bionatur Solutions, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	29/21/29	CI
ADL Bionatur Solutions, S.A. announced that it has received ?12 million in funding from Kartesia Advisor LLP	20/21/20	CI
Adl Bionatur Solutions, S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	11/21/11	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	11/21/11	CI
ADL Bionatur Solutions, S.A. announced that it expects to receive €5 million in funding	19/21/19	CI
ADL Bionatur Solutions, S.A. announced that it has received €12 million in funding from Kartesia Advisor LLP	26/21/26	CI
Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. and Black Toro Capital LLP.	07/20/07	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	22/20/22	CI
ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million	02/19/02	CI
ADL Bionatur Solutions Announces Revenue Results for the Third Quarter and Nine Months of 2019; Confirms Revenue Guidance for the Full Year of 2019	14/19/14	CI
ADL Bionatur Solutions Announces Earnings Results for the First Six Months of 2019; Provides Guidance for the Full Year 2019	10/19/10	CI
ADL Bionatur Solutions, S.A. announced that it has received €25 million in funding from Kartesia Advisor LLP	12/19/12	CI
ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019	07/19/07	CI
ADL Bionatur Solutions Enters into an Initial EUR 13 Million Strategic Alliance with Japanese Pharma Company	07/19/07	CI
ADL Bionatur Solutions and Amyris, Inc. Expand Contract to 2020	22/19/22	CI
ADL Bionatur Solutions Increases 2019 Production for Global Nutrition Company for Additional Revenues of over EUR 2.5 Million	09/19/09	CI
ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019	06/19/06	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	12/19/12	CI
Nutricion Center NC and ADL Bionatur Solutions Sign Strategic Alliance to Tackle Weight Control by Rebalancing the Gut Microbiome	19/19/19	CI
Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand	10/18/10	CI

Chart Biotechnology Assets, S.A.

Duration

Period

More charts

Company Profile

Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Firmâs main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOTECHNOLOGY ASSETS, S.A.	-15.91%	2.29Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	12TCr
REGENERON PHARMACEUTICALS, INC.	+16.60%	11TCr
ARGENX SE	+18.43%	2.59TCr
BIONTECH SE	-24.33%	1.93TCr
GENMAB A/S	-19.14%	1.6TCr
BEIGENE, LTD.	-17.95%	1.57TCr
WUXI APPTEC CO., LTD.	-46.81%	1.49TCr
SAREPTA THERAPEUTICS, INC.	+58.78%	1.45TCr
NEUROCRINE BIOSCIENCES, INC.	+4.91%	1.39TCr

Bio Therapeutic Drugs